

Indivior Statement on Court Decision

Slough, UK, 20 November 2018 – Indivior PLC (LON: INDV)

“Indivior is disappointed that the U.S. Court of Appeals for the Federal Circuit has vacated the preliminary injunction against Dr. Reddy’s Laboratories (“DRL”). Indivior will continue to vigorously pursue ongoing infringement cases against DRL to protect its SUBOXONE® (buprenorphine and naloxone) Sublingual Film patent portfolio.

The Company is in the process of interpreting the ruling in its entirety and will issue a statement on its implications once this review has been completed.”

For Further Information

Investor Enquiries	Jason Thompson	VP Investor Relations, Indivior PLC	+1 804 379 1033 jason.thompson@indivior.com
Media Enquiries	Jonathan Sibun	Tulchan Communications	+44 207 353 4200
		US Media Enquiries	+1 804 594 0836 Indiviormediacontacts@indivior.com

Corporate Website www.indivior.com